en
Scientific article
English

STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension

Published inCirculation, vol. 129, no. 19, p. 1914-1923
Publication date2014
Abstract

The double-blind, placebo-controlled Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension (STARTS-1) study assessed sildenafil in pediatric patients with pulmonary arterial hypertension; improved hemodynamics and exercise capacity occurred in medium- and high-dose groups. STARTS-2 was the extension study.

Keywords
  • Administration, Oral
  • Adolescent
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Exercise Tolerance/drug effects/physiology
  • Familial Primary Pulmonary Hypertension
  • Female
  • Hemodynamics/drug effects/physiology
  • Humans
  • Hypertension, Pulmonary/drug therapy/mortality/physiopathology
  • Infant
  • Kaplan-Meier Estimate
  • Male
  • Piperazines/administration & dosage
  • Purines/administration & dosage
  • Regression Analysis
  • Sulfones/administration & dosage
  • Survival Rate
  • Time Factors
  • Treatment Outcome
  • Vasodilator Agents/administration & dosage
Citation (ISO format)
BARST, Robyn J et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. In: Circulation, 2014, vol. 129, n° 19, p. 1914–1923. doi: 10.1161/CIRCULATIONAHA.113.005698
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0009-7322
553views
0downloads

Technical informations

Creation03/16/2015 2:05:00 PM
First validation03/16/2015 2:05:00 PM
Update time03/14/2023 11:08:34 PM
Status update03/14/2023 11:08:34 PM
Last indexation01/16/2024 5:38:40 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack